author-photo

Lei Hua

Agios Pharmaceuticals

9

Papers

98

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (1)
Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency

2019 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (44)
Genotype-Response Correlation in DRIVE PK, a Phase 2 Study of AG-348 in Patients with Pyruvate Kinase Deficiency

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)